Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study

Abstract Background This study assessed the real-world effectiveness of the ChAdOx1 nCoV-19 vaccine in adults against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, symptomatic infection, and severe coronavirus disease 2019 (COVID-19) during periods of Beta and Delta variant...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul-Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al-Kuwari, Adeel A. Butt, Hamad Eid Al-Romaihi, Mohamed H. Al-Thani, Abdullatif Al-Khal, Roberto Bertollini, Laith J. Abu-Raddad
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-08-01
Edice:	BMC Infectious Diseases
Témata:	COVID-19 Vaccine Effectiveness Vaxzevria Astrazeneca ChAdOx1 nCoV-19
On-line přístup:	https://doi.org/10.1186/s12879-025-11410-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!